Answers are grounded in this paper and cite their sources.
Hepatic steatosis and lactic acidosis have been reported sporadically with the administration of antiretroviral nucleoside analogs (ANA), such as zidovudine, didanosine, zalcitabine, combivir (a combination of zidovudine and lamivudine) and lamivudine [1–5]. ANA require phosphorylation to the corresponding mono-, di-, and triphosphate by cellular host kinases to exert their antiretroviral activity. Triphosphate inhibits the viral reverse transcriptase and terminates the growing viral DNA chain. Triphosphate also inhibits host DNA polymerase, resulting in compensatory glycolysis and lactic acidosis [6]. Abnormal mitochondrial oxidation of free fatty acids causes the accumulation of neutral fat in liver cells, manifesting as severe hepatomegaly with macrovesicular steatosis. There appears to be some degree of intracellular carnitine depletion as a result of abnormal uptake by liver cells. Therapy with oral carnitine and antioxidants such as co-enzyme Q and vitamin C may be beneficial [4,7], but experience with these agents is limited. We recently cared for three patients with HIV infection who developed lactic acidosis and hepatic steatosis while receiving stavudine and lamivudine. 63% of the previously reported cases have been women (letter, Glaxo Wellcome). All three of our patients were also women. Case 1 A 37-year-old HIV-infected woman with a CD4 T cell count of 201/mm3 on triple drug therapy with lamivudine, stavudine and indinavir for the past 8 months presented with epigastric pain, anorexia and vomiting for 2 weeks. Physical examination revealed tachypnea and hepatomegaly. Laboratory data showed lactic acidosis (serum lactate of 4.9 mEq/l), elevated liver enzymes [aspartate transaminase (AST) 219 IU/l, normal 0–45 IU/l] and prothrombin time (14.19 s, normal 9.8–13.8 s). Chest radiograph was normal. The patient required mechanical ventilation and a pulmonary artery catheter was inserted. Hypoperfusion and an infection as a cause of lactic acidosis were excluded. Extensive fatty infiltration of the liver was present on computed tomography (CT) scan of the abdomen. The hospital course was complicated by pancreatitis and acute respiratory distress syndrome. Antiretroviral medications were stopped and therapy with co-enzyme Q, carnitine and vitamin C was initiated. Serum lactic acid and hepatic transaminases returned to normal over 4 weeks. The patient was weaned off the ventilator 4 months after admission. Case 2 A 40-year-old HIV-infected woman with a CD4 T cell count of 150/mm3 on stavudine, lamivudine, nelfinavir and trimethoprim/sulfamethoxazole for 1 month was admitted with dyspnea, dysphagia, and vomiting for 2 weeks. Physical examination showed hepatomegaly. She had lactic acidosis (serum lactate 9.4 mEq/l) and AST of 48 IU/L (normal 0–40 IU/l). Chest X-ray was normal. Abdominal CT scan showed hepatic steatosis. The patient developed respiratory failure, was intubated and placed on a mechanical ventilator. Lactic acidosis continued to worsen despite hemodynamic support, and the patient died 5 days after admission. Autopsy showed massive hepatomegaly with steatosis. All special stains and cultures were negative. Case 3 A 36-year-old HIV-infected woman with a CD4 cell count of 8/mm3 presented with diarrhea and vomiting for 4 days. She had been receiving stavudine, saquanavir, retonavir, didanosine for an unknown period. Physical examination revealed oral thrush and hepatomegaly. The patient was admitted and treated with fluconazole and antiretroviral agents. Vomiting and diarrhea persisted. Lactic acidosis (serum lactate 11.4 mEq/l) was identified 2 weeks after admission. Serum AST was elevated (118 IU/l, normal 0–40 IU/l). All cultures were negative. Abdominal sonogram showed hepatic fatty infiltration and acute pancreatitis. ANA were stopped. The patient required ventilatory support. A pulmonary artery catheter showed a hyperdynamic state with normal filling pressures. Despite an improvement in lactacidemia and liver function, the patient died 8 weeks after presentation. Consent for autopsy was not granted. In summary, patients on chronic nucleoside analog antiretroviral therapy including newer agents such as stavudine and lamivudine may develop this steatosis–lactic acidosis syndrome (SLAS). The initial presentation is usually with gastrointestinal complaints. Patients receiving ANA should be closely monitored for evidence of liver dysfunction or lactic acidosis and the drugs discontinued at the earliest suspicion of the above-mentioned abnormalities. Empiric therapy with antioxidants and carnitine replacement may be of value in reducing the high morbidity and mortality associated with SLAS. We believe that the survival of the first patient in our series may be attributed to the administration of co-enzyme Q, carnitine and vitamin C.
No takes yet. Share an insight, caveat, or question.
Johri et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: